MedCity News November 18, 2019
Unless IT concerns related to precision medicine are addressed, healthcare will simply reenact a mistake made years ago with EHRS valuable data that can directly impact care will be locked in a silo, unavailable during clinical decision-making.
Progress in genomic science has been astronomical over the past few years. In fact, the tipping point that validated the clinical significance of genetic/genomic testing is barely visible in the rearview mirror. As a result, stakeholders ranging from clinicians to regulatory agencies, to professional associations, to payers have begun championing the value that precision medicine delivers in terms of better diagnoses and more effective therapeutic interventions.
For example, in educational materials explaining incidence of dilated cardiomyopathy (DCM), the American Heart Association notes that...
Today's Sponsors
Today's Sponsor